Cytokinetics recently launched a Phase 1b clinical trial designed to evaluate the effect of CK-2127107 on physical function in older adults with limited mobility due to diseases associated with muscular weakness and/or fatigue, including chronic obstructive pulmonary disease (COPD). The therapeutic candidate is a next-generation fast skeletal muscle troponin activator…
U.S. regulators have agreed to Sunovion Pharmaceuticals’ request for another review of its SUN-101/e-Flow system for treating chronic obstructive pulmonary disease. The review will cover a New Drug Application that Sunovion resubmitted after the Federal Drug Administration decided the company did not have to conduct additional clinical trials of SUN-101/e-Flow’s safety and effectiveness.
Five European countries have agreed to Verona Pharma’s plan to begin enrolling patients in a Phase 2b clinical trial of RPL554 as a maintenance treatment for chronic obstructive pulmonary disease, or COPD. The trial will be conducted in the United Kingdom, Germany, Romania, Bulgaria, and the Czech Republic. Verona expects to start…
The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently approved Daxas (roflumilast), developed by AstraZeneca, as a treatment for chronic obstructive pulmonary disease (COPD). The new indication could potentially benefit about 122,000 adults in the U.K. who are estimated to be eligible to receive Daxas, according…
The effects of vaporized cannabis on symptoms associated with chronic obstructive pulmonary disease (COPD) are the target of a new clinical trial that stems from a partnership between medical cannabis products company Tilray and the Research Institute of the McGill University…
The lung therapy developer Pulmatrix has obtained global rights to RespiVert’s respiratory-disease treatments under a licensing arrangement. Under the deal, Pulmatrix gained access to the kinase inhibitors that RespiVert has developed for lung conditions such as chronic obstructive pulmonary disease (COPD). Pumatrix also develops kinase inhibitors. RespiVert is a subsidiary of Janssen…
Sunovion Pharmaceuticals has received a complete response letter from the U.S. Food and Drug Administration (FDA), clearing the Massachusetts company from having to conduct further clinical trials for approval of its SUN-101/eFlow (glycopyrrolate) therapy to treat chronic obstructive pulmonary disease (COPD). According to a corporate press release, the CRL clears Sunovion…
Dutch healthcare conglomerate Royal Philips has purchased RespirTech, a leading manufacturer of airway clearance therapy vests for patients with chronic obstructive pulmonary disease (COPD) and other severe lung conditions. With this new acquisition, Philips expands its respiratory care portfolio, strengthening its presence in the hospital and home care markets — especially…
A recent study, co-sponsored by Royal Philips, showed that using home noninvasive ventilation in addition to home oxygen therapy (HOT) could effectively delay hospital readmissions and increase survival in patients with advanced chronic obstructive pulmonary disease (COPD) after a life-threatening respiratory event or exacerbation. The study, “Effect of Home Noninvasive…
Using a ventilator to control the level of supplemental oxygen a chronic obstructive pulmonary disease (COPD) patient receives halved patients’ trips to the hospital from disease flare-ups, according to a clinical trial. Britishers researchers conducted the study, which they dubbed the Home Oxygen Therapy-Home Mechanical Ventilation (HOT-HMV) trial (…
Get regular updates to your inbox.